Last reviewed · How we verify

Adapalene/Benzoyl Peroxide Gel 0.3-2.5%

Derm Research, PLLC · FDA-approved active Small molecule

Adapalene/Benzoyl Peroxide Gel 0.3-2.5% is a Retinoid + peroxide combination Small molecule drug developed by Derm Research, PLLC. It is currently FDA-approved for Acne vulgaris. Also known as: Epiduo Forte 0.3%-2.5% Topical Gel.

Adapalene is a retinoid that normalizes skin cell differentiation and reduces inflammation, while benzoyl peroxide kills acne-causing bacteria and provides additional antimicrobial activity.

Adapalene is a retinoid that normalizes skin cell differentiation and reduces inflammation, while benzoyl peroxide kills acne-causing bacteria and provides additional antimicrobial activity. Used for Acne vulgaris.

At a glance

Generic nameAdapalene/Benzoyl Peroxide Gel 0.3-2.5%
Also known asEpiduo Forte 0.3%-2.5% Topical Gel
SponsorDerm Research, PLLC
Drug classRetinoid + peroxide combination
TargetRetinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Adapalene binds to retinoic acid receptors to regulate gene expression, reducing comedone formation and normalizing follicular epithelial differentiation. Benzoyl peroxide acts as an oxidizing agent that generates reactive oxygen species, killing Cutibacterium acnes (formerly Propionibacterium acnes) and reducing bacterial resistance. Together, they provide complementary anti-inflammatory and antimicrobial effects for acne treatment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Adapalene/Benzoyl Peroxide Gel 0.3-2.5%

What is Adapalene/Benzoyl Peroxide Gel 0.3-2.5%?

Adapalene/Benzoyl Peroxide Gel 0.3-2.5% is a Retinoid + peroxide combination drug developed by Derm Research, PLLC, indicated for Acne vulgaris.

How does Adapalene/Benzoyl Peroxide Gel 0.3-2.5% work?

Adapalene is a retinoid that normalizes skin cell differentiation and reduces inflammation, while benzoyl peroxide kills acne-causing bacteria and provides additional antimicrobial activity.

What is Adapalene/Benzoyl Peroxide Gel 0.3-2.5% used for?

Adapalene/Benzoyl Peroxide Gel 0.3-2.5% is indicated for Acne vulgaris.

Who makes Adapalene/Benzoyl Peroxide Gel 0.3-2.5%?

Adapalene/Benzoyl Peroxide Gel 0.3-2.5% is developed and marketed by Derm Research, PLLC (see full Derm Research, PLLC pipeline at /company/derm-research-pllc).

Is Adapalene/Benzoyl Peroxide Gel 0.3-2.5% also known as anything else?

Adapalene/Benzoyl Peroxide Gel 0.3-2.5% is also known as Epiduo Forte 0.3%-2.5% Topical Gel.

What drug class is Adapalene/Benzoyl Peroxide Gel 0.3-2.5% in?

Adapalene/Benzoyl Peroxide Gel 0.3-2.5% belongs to the Retinoid + peroxide combination class. See all Retinoid + peroxide combination drugs at /class/retinoid-peroxide-combination.

What development phase is Adapalene/Benzoyl Peroxide Gel 0.3-2.5% in?

Adapalene/Benzoyl Peroxide Gel 0.3-2.5% is FDA-approved (marketed).

What are the side effects of Adapalene/Benzoyl Peroxide Gel 0.3-2.5%?

Common side effects of Adapalene/Benzoyl Peroxide Gel 0.3-2.5% include Erythema, Scaling/peeling, Dryness, Irritation, Photosensitivity.

What does Adapalene/Benzoyl Peroxide Gel 0.3-2.5% target?

Adapalene/Benzoyl Peroxide Gel 0.3-2.5% targets Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide) and is a Retinoid + peroxide combination.

Related